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The objective of this studywas to perform a structural characterization and evaluate the in vitro safety profile and in vitro antioxidant
activity of liquid crystalline systems (LCS) with and without retinyl palmitate (RP). LCS containing polyether functional siloxane
(PFS) as a surfactant, silicon glycol copolymer (SGC) as oil phase, and water in the ratios 30 : 25 : 45 and 40 : 50 : 10 with (OLSV
= RP-loaded opaque liquid system and TLSV = RP-loaded transparent liquid system, respectively) and without (OLS and TLS,
respectively) RP were studied. Samples were characterized using polarized light microscopy (PLM) and rheology analysis. In vitro
safety profile was evaluated using red cell hemolysis and in vitro cytotoxicity assays. In vitro antioxidant activity was performed by
the DPPHmethod. PLM analysis showed the presence of lamellar LCS just to TLS. Regardless of the presence of RP, the rheological
studies showed the pseudoplastic behavior of the formulations. The results showed that the incorporation of RP in LCS improved
the safety profile of the drug.In vitro antioxidant activity suggests that LCS presented a higher capacity to maintain the antioxidant
activity of RP. PFS-based systems may be a promising platform for RP topical application for the treatment of skin aging.
1. Introduction
Currently, the demand for products that reduce skin aging is
constantly growing because people want to stay young as long
as possible. Cosmeceuticals (cosmetics producing beneficial
results for the body, for example, the effects of antifree
radicals) represent one of the largest growing segments of the
skin care market, especially for products that are designed to
prevent and treat skin aging [1, 2].
Aging is a natural and inevitable process that reverses the
biological characteristics acquired during development and
leads to cell death [3].Thenatural process of skin rejuvenation
slows dramatically and the skin becomes thinner and drier,
losing elasticity [4]. Skin aging is influenced by several factors
including genetic factors, environmental exposures (ultra-
violet radiation (UV), xenobiotics, and stress mechanisms),
hormonal changes, and metabolic processes (generation of
reactive oxygen species as chemically activated sugars and
aldehydes). All of these factors act together in changing the
structure, function, and appearance of the skin [5].
The use of retinoids has been highlighted for the treat-
ment of photoaging, and there are many different brands
and formulations currently available in the market that
employ such substances. A randomized clinical study showed
beneficial results of retinoids in photoaging, in addition to
repairing and preventing skin aging [6].
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Figure 1: Molecular structure of retinyl palmitate.
Studies have indicated that retinoids may have specific
effects on the receptor resulting in decreased skin roughness
and skin facial wrinkles [7]. A study with 24 Korean women
for 24 weeks showed improvement in skin roughness and fine
wrinkles [8, 9].
Retinyl palmitate, whose molecular structure is shown
in Figure 1, is an ester of retinol and is the major form of
vitamin A found in the epidermis. This compound has been
widely used in pharmaceutical and cosmetic formulations [3].
It has a high molecular weight and a stable formulation. To
be active, RP should be enzymatically converted in the skin
to retinol by cleavage of the ester linkage and must then be
converted to tretinoin via oxidative processes. The topical
administration of RP for 14 days in rats resulted in increased
protein and collagen and an epidermal thickening [6].
The main obstacle to the use of topical retinoids is
the high incidence of skin irritation. Patients may develop
dermatitis with redness and tenderness of the skin. This
usually occurs within two to four weeks after initiation
of treatment and usually disappears when the treatment is
continued. Nevertheless, many patients discontinue therapy
because of these reactions. It has been found that derivatives
of retinol such as RP do not produce the same irritant effects
as retinoic acid and induce the same cellular and molecular
changes observed with the application of retinoic acid [10].
Sorg et al. (2005) demonstrated that, although the
amounts of RP naturally present in the epidermis are too
low to provide effective and efficient protection against
UV radiation, these retinoids can easily be administered
topically in order to promote effective protection. This was
confirmed by some studies, including one conducted in
human volunteers who were subjected to UVB light to assess
DNA damage and erythema. The participants were treated
with a commercial sunscreen (octyl methoxycinnamate) and
one containing RP, and it was observed that RP inhibited the
formation of thymine dimers (an indicator of DNA damage)
and erythema [3]. Another study showed that DNA damage
and apoptosis were inhibited in mice by the application of
topical retinoic acid, retinaldehyde, retinol, and RP [11].
Currently, the development of pharmaceutical and cos-
metic technology is not restricted only to the discovery of
new molecules but also to the development of new systems
to deliver active ingredients or optimize their release [12].
The combination of consumer desire and the development of
these technologies has led to the emergence of new systems
with specific properties, capable of incorporating substances
with different profile releases optimized for application on
different areas [13]. Among the systems developed or with
applicability for topical skincare cosmetics, nanotechnology-
based drug delivery systems are promising vehicles for
dermal and transdermal release of active compounds, par-
ticularly the liquid crystalline systems (LCS), multiple emul-
sions, and nanoemulsions [13, 14]. LCS have applications in
cosmetic and pharmaceutical formulations. They are able to
promote the encapsulation of active ingredients, allowing for
sustained release of the same, as well as giving protection of
drugs and photosensitivity depending on the microstructure,
increasing the stability of these systems to reduce coalescence
and change in viscosity [13, 15, 16].
Furthermore, LCS can maintain therapeutic response for
a longer period of time, improve drug efficacy and solubility,
decrease side effects, and interfere in skin hydration. The
incorporation of RP within LCS phases provided a significant
reduction in the orbicular wrinkles of human volunteers [17].
Studies involving nanotechnology seek to implement new
technological approaches to extend the benefits provided by
drug delivery systems. The development of an effective, safe,
and reliable carrier systemwhich exhibits good bioavailability
and pharmacodynamics and also reduces side effects is a goal
for many researchers. Therefore, finding a system that meets
those requirements would be extremely valuable and SLC are
potential candidates [13, 18].
The objective of the present study was to perform a
structural characterization and evaluate the in vitro safety
profile and antioxidant activity of lamellar LCS, with and
without RP.
2. Materials and Methods
2.1. Materials. Polyether functional siloxane, DC 5329 (S),
and silicon glycol copolymer, DC 193 (O), were purchased
from Dow Corning (Michigan, USA), and retinyl palmitate
(RP) 1,000,000 IU/g was purchased from Roche (Greenzach-
Wyhlen, Germany). High purity water (W) from a Millipore
Milli-Q plus purification system was used throughout.
2.2. Formulation Preparation. The preparation has been
described previously [17]. The samples were prepared by
heating a mixture of O and S to 45∘C. W was heated to
40∘C and then carefully added under gentle and constant
stirring until the mixture reached room temperature. The
resulting systems, containing various proportions of the
components, were characterized using a pseudoternary phase
diagram in order to define the proportions that formLCS [17].
The proportions of each component were calculated from
titrations of the binary mixtures of oil phase and surfactant
with water. The transitions from an opaque semisolid phase
to a transparent viscous system (TVS), viscous and opaque
system (OVS), and an opaque liquid system (OLS), as well as
a transparent liquid system (TLS) and phase separation (PS),
were defined. Diagrams were produced for the RP-loaded
(1%) and RP-unloaded mixtures.
2.3. Polarized Light Microscopy. A small amount of the
formulations was placed on a glass slides, covered with
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a cover slip, and examined with the aid of a polarized
light microscope (Jenamed 2, Carl Zeiss-Jena) to judge the
homogeneity of the dispersions and the presence of optically
anisotropic areas by the patterns formed with the sample
between crossed polarizers.
2.4. Rheology Analysis. The rheological determination of for-
mulations was carried out with a controlled-stress rheometer
(model RS-1, Haake RheoStress) with plate-plate geometry.
This geometry consists of two stainless steel plates 2 cm in
diameter with a gap of 200𝜇m between the plates. Samples
were carefully applied to the lower plate, ensuring that for-
mulation shearing was minimized, and allowed to equilibrate
for at least 3 minutes prior to analysis. The experiments were
carried out with shear rates in the range of 0.001–30 s−1.
The shear rate region used was selected on the basis of the
strength of resistance to the applied stresses. The rheological
measurements were performed on both the up and down
curve. All rheological determinations were carried out on all
samples at 25.0 ± 0.2∘C.
2.5. In Vitro Biological Assays
2.5.1. Erythrocyte Hemolysis. The erythrocyte hemolysis
assay was performed using the experimental procedure
described by Jumaa et al. [19] and Huang et al. [20]. Briefly,
before use, freshly collected human blood (O positive) was
washed three times with 0.01M Tris-HCl with a pH 7.4
containing 0.15MNaCl (Tri-saline). A suspension of 1% (v/v)
erythrocytes was prepared with packed red blood cells resus-
pended inTris-saline. RP-loaded LCS, RP-unloaded LCS, and
RP free were dissolved in Tris-saline to a final concentration
of 27𝜇M. As a positive control (100% lysis), a 1% (v/v)
Triton X-100 solution was used. After incubation for 1 hour at
37∘C, the samples were centrifuged at 3000×g for 2minutes.
Aliquots of 100 𝜇L of the supernatant were transferred to
96-well microplates, and the absorbance was determined at
405 nm using a BioRad Model 3550-UV (USA) microplate
reader. The assay was performed in triplicate. The percentage
of hemolysis was calculated using the following equation: %
hemolysis = (absorbance of the test sample/absorbance at
100% lysis) × 100.
2.5.2. In Vitro Nonspecific Cytotoxicity. In vitro testing for
analysis of the cytotoxicity of the formulationswas performed
using J-774 mouse macrophages as template. Cells were
seeded in bottom microplates (Nunclon) with 96 wells and
a density of 2.5–10.0 × 105 cells/well with different doses of
the formulation and free RP (18.6, 10, 5, and 1 𝜇M) or vehicle
control for 48 hours. The cells were washed with PBS after
removal of the compounds and cell viability was assessed by
colorimetry formazan (MTT).
The method of 3 [4,5-dimethylthiazol-2-yl]-2,5-diphen-
yltetrazolium bromide (MTT) is simple, reliable, and repro-
ducible colorimetric method for measuring mitochondrial
metabolic reduction of yellow tetrazolium salt to the insoluble
formazan crystals in aqueous solution of viable cells. Cells
and MTT (0.4mg/mL) were incubated at 37∘C for 3 hours.
Subsequently, the supernatant was removed and formazan
crystals were dissolved in DMSO (180mL). The plates were
agitated for 10 minutes and optical density was measured
using a multiwall spectrophotometer operating at 560 nm.
Concentrations were tested in triplicate using six additional
controls (cells in medium). Cell viability was calculated
using the following equation: cell viability (%) = [OD
560
(sample)/OD
560
(control)] × 100.
2.6. In Vitro Antioxidant Activity. Free radical scavenging
activity was evaluated by the 2,2-diphenyl-1-picrylhydrazyl
(DPPH) test with modifications [21]. One hundred micro-
liters of RP free, formulations, or control (ethanol; 10–
60 𝜇g/mL) was added to 3.9mL of DPPH solution (ethanol;
60 𝜇M). After 30 minutes storage in a dark place, the
absorbance measures were calculated using a spectropho-
tometer at 517 nm. All measurements were repeated three
times. Free radical scavenging activity was calculated using
the following formula: % inhibition DPPH = [(𝐴
0
− 𝐴
1
)/
𝐴
0
× 100], where 𝐴
0
represents absorbance of control and
𝐴
1
represents absorbance of sample. The IC
50
value was
determined by plotting concentration of formulations versus
the percentage keeping DPPH at a steady state [21].
2.7. Statistical Analyses. Data were analyzed using the mean
and standard deviation and compared by analysis of variance
(ANOVA). The Tukey test was used to assess significant
differences between samples, where values 𝑃 < 0.05 were
considered statistically significant. The program Origin 7.0
SRO was used for the treatment of the data.
3. Results and Discussion
Formulations were prepared with different surfactant/oil/
water ratios, with and without RP. The compositions were
based on the pseudoternary phase diagram previously con-
structed for the samemixture in the experimental conditions
[16]. Two formulations were selected for tests—OLS, consti-
tuted by 30% surfactant (polyether functional siloxane, PSF),
25% of oil phase (silicon glycol copolymer, SGC), and 45% of
water, and TLS—constituted by 40% PSF, 50% SGC, and 10%
water. To each of these systems, 1% RP was added, yielding
the formulations OLSV and TLSV. The development and
characterization of the system were crucial to the choice of
the formulation study. The ternary phase diagram (Figure 2)
obtained had extensive concentration transparent systems
(TVS and TLS), since the oil phase of the system also has
surfactant properties. At low concentrations of water and oil
intermediates OVS andOLS were formed and concentrations
of oil and water phase below 30% were observed PS.
The determination of the optical properties of the for-
mulations was performed observing the sample between
crossed polarizers. Lamellar and hexagonal mesophases are
anisotropic, while cubic mesophases are isotropic [22, 23].
The presence of Maltese crosses for TLS, Figure 3(a), showed
the presence of a lamellar liquid crystal, LCS.The formulation
OLS did not present liquid crystalline mesophases, as shown
by the homogenous dark field (Figure 3(b)) [18].
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Figure 2: Ternary phase diagram, with l and the square (◻) representing the selected regions, where TVS is transparent viscous system, OVS
is opaque and viscous system, TLS is transparent liquid system, OLS is opaque liquid system, and PS is phase separation.
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Figure 3: Images obtained by Polarized light microscopy: (a) transparent liquid system (TLS) showed Maltese crosses; (b) opaque liquid
system (OLS) showed dark field. The objects are air bubbles (magnified of 20x).
In the pharmaceutical development of cosmetics, the
study of rheology (flow characteristics) has fundamental
importance when considering the manufacturing process
and the preparation, transportation, storage, and use by
consumers [24, 25]. The rheological analysis was made in the
form of rheograms, showing the relationship between shear
stress (𝜎) and shear rate (𝛾). In Figure 4 we can observe the
relationship between 𝜎 and 𝛾 for all of the formulations. For
some combinations the values of the shear stress are different
for the curves with increased and reduced shear rate. This
characteristic is typical of thixotropic materials [26].
The viscosity decreases with increasing shear rate which
occurred in the studied system irrespective of the definition
of viscosity used and is a characteristic of pseudoplastic
fluid [26]. This makes the product suitable for topical use,
because of the initial shear to apply the sample; the reduced
viscosity results in a good spreading during application and
in the formation of uniform film on the skin surface [27–
29]. In the formulations, by decreasing shear rate the values
return to baseline, the rheological behavior is reversible, and
the viscosity returns to the initial value sometime after the
initial step deformation [30–33]. This phenomenon is also
useful for skin applications, since the increased viscosity
assists in retaining the formulation in place. As for the OLS
sample compared with sample TLS a pronounced decrease in
viscosity was observed with increasing shear rate. For both
formulations, the addition of vitamin increased the viscosity
of the formulations.
The behavior of these formulations can be reaffirmed
based on power law, described in the following equation:
𝜏 = 𝑘 ⋅ 𝛾
𝜂, where 𝑘 and 𝜂 values are related to the consistency
and flow index, respectively. Thus, in this model, values of 𝑛
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Figure 4: Rheogram of the systems studied, where OLS is opaque
liquid system, OLSV is RP-loaded opaque liquid system, TLS is
transparent liquid system, and TLSV is RP-loaded transparent liquid
system.The solid symbols represent the upper curves and the hollow
symbols represent the lower curves.
Table 1: Index of flow (𝜂) and consistency index (𝑘) of the
formulations.
Formulations 𝜂 𝑘
OLS 0.28834 19.2766
OLSv 0.82859 5.00762
TLS 0.82742 5.60389
TLSv 0.78206 8.36384
OLS: opaque liquid system, OLSv: RP-loaded opaque liquid system, TLS:
transparent liquid systems, and TLSv: retinyl palmitate-loaded transparent
liquid systems.
greater than 1 represent dilatant fluid, values of 𝑛 smaller than
1 represent a pseudoplastic fluid, and finally values of 𝑛 equal
to 1 represent Newtonian fluid [34].
In Table 1, the values of 𝜂 and 𝑘 for all formulations as
compared to the rating of the rheogram are presented.
The formulations outlined in Table 1 (OLS, OLSV, TLS,
and TLSV) show that all values of 𝜂 are smaller than 1, indicat-
ing pseudoplastic fluids which agree with the interpretation
based on the observation of the rheogramof Figure 4. InOLS,
after adding RP, there was an increase in the value of 𝜂, from
0.28834 to 0.82859. Nevertheless, the same was not observed
with TLS andTLSV, and close values were found among them.
3.1. In Vitro Biological Assays. The in vitro test is important
for screening a substance which can be used subsequently
in preclinical trials. In addition, it is able to provide initial
parameters such as viability and therapeutic targets for
subsequent reviews [35].
The materials used in the formulations present well-
known safety profiles; however, these mixtures have been
shown to form structures which may change the barrier
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Figure 5: Percentage of cell viability of RP free, transparent liquid
system (TLS), opaque liquid system (OLS), RP-loaded transparent
liquid system (TLSV), and RP-loaded opaque liquid system (OLSV).
properties of the skin. Therefore, it is important to study the
safety of these new systems on the skin.
Erythrocyte membranes have been broadly used for in
vitro cytotoxicity assays because they are easily isolated by
centrifugation and obtained by venipuncture.They represent
a good model to evaluate the interaction of drugs with
the membrane and thus provide information about changes
in the composition of lipids, enzymes, or other membrane
proteins [36].
The safety profile was assessed using the hemolysis of
red blood cells and in vitro cytotoxicity assays. Free RP
caused 4.69 ± 0.54% lysis of erythrocyte membranes. TLS
and OLS caused lysis of 1.23% ± 0.69 and 1.49 ± 0.35% of
the erythrocyte membranes, respectively. The incorporation
of RP in LCS—TLSV and OLSV—was 3.19 ± 1.07% and
3.42 ± 0.54%, respectively and showed decreased erythrocyte
lysis compared to the free RP. Thus, all systems showed
a tolerable hemolysis of erythrocytes. The positive control
was represented by 100% hemolysis of erythrocytes using
Triton X-100, a known hemolytic agent, thus validating the
experiment. The study results indicate that the treatment
developed with lipid systems showed less toxicity, which is
a potential alternative to therapeutic applications [20].
Similarly, the safety profile of praziquantel (PZQ) was
evaluated in studies using red cell hemolysis and showed that
the encapsulation of PZQ in nanostructured lipid carriers
improved the safety profile of the drug with decreased lysis
of erythrocytes in relation to the free PZQ. The systems
demonstrated improved efficacy in comparison with free
PZQ [37].
In vitro cytotoxicity was performed using J-774 mouse
macrophages as a cellular model. The data are shown as a
percent of cellular viability (Figure 5).
Abbasalipourkabir et al. (2011) say that some factors may
influence the cytotoxic effect of the particles: adherence to
the cell membrane, particle internalization, and degradation
products in the cell culture medium or in the intracellular
6 BioMed Research International
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loaded opaque liquid system, and OLS: opaque liquid system.
environment [38]. Nevertheless, cell types may exhibit differ-
ent changes in susceptibility to particulate carriers since the
system contains natural lipids to be well tolerated by the body
[39].
Cell viability showed that free RP did not kill normal
macrophages presenting a result superior to 92%. Moreover,
the RP-unloaded and RP-loaded CLS also did not show toxic
activity.Therefore, the results indicate the safety and biocom-
patibility of the formulations and free RP for eukaryotic cells
[37].
The formulations with or without the addition of RP were
evaluated for in vitro antioxidant activity over a period of 28
days. The results obtained are shown in Figure 6.
The antioxidant activity was measured based on the
methodology of Blois [21], who uses the stable radical DPPH
which is reduced by antioxidants. The results were expressed
as DPPH inhibition (%).
It can be seen that over the period of 28 days there
was a decrease in antioxidant power for all the experimental
groups, with the most marked decrease for the RP free and
a statistical difference between the samples (𝑃 < 0.05).
The lesser destabilization of the samples is probably due to
increased stabilization of the vitamin in the formulations.
Moreover, the antioxidant activity was greater for TLSV
compared to OLSV, suggesting increased stability of the
vitamin in the lamellar LCS. This effect has been found in
the literature; the liquid crystals can protect the formulation
while preventing the degradation of the active ingredient
[13, 16, 35, 40, 41].
Therefore, all formulations maintained the antioxidant
properties of the RP, whichmakes them promising as vehicles
for incorporation of the vitamin, aiming its topical applica-
tion at the treatment of aging skin.
4. Conclusion
The results suggest that the LCS containing polyether func-
tional siloxane (PFS) as surfactant, silicon glycol copolymer
(SGC) as oil phase, and water in the ratios 40 : 50 : 10 with RP
(TLSV) presented a lamellar phase and pseudoplastic behavior
in rheological analysis. In vitro safety profile showed that
this formulation is not cytotoxic and in vitro antioxidant
activity suggested that LCS presented a higher capacity to
maintain the antioxidant activity of RP. PFS-based systems
may be a promising platform for RP topical application for
the treatment of skin aging.
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